WO2012155376A1 - 一种四磨汤制剂的检测方法 - Google Patents
一种四磨汤制剂的检测方法 Download PDFInfo
- Publication number
- WO2012155376A1 WO2012155376A1 PCT/CN2011/075806 CN2011075806W WO2012155376A1 WO 2012155376 A1 WO2012155376 A1 WO 2012155376A1 CN 2011075806 W CN2011075806 W CN 2011075806W WO 2012155376 A1 WO2012155376 A1 WO 2012155376A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- column
- tang
- preparation
- synephrine
- oral liquid
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
Definitions
- the invention relates to a method for detecting a four-mill soup preparation. Background technique
- Ciobium is a prescription for quickly eliminating gastrointestinal stagnation and enhancing digestive function.
- the main ingredients of this party include woody, oyster shell, black peony and betel nut.
- the woody, clam shells are wide and the stomach, the betel nut is down, and the black medicine is cold and painful. All kinds of medicines are used together to play the role of qi stagnation, swelling and pain relief. It is mainly used for infants' dairy food stagnation, middle-aged and elderly qi stagnation, and recovery of gastrointestinal function after abdominal surgery and postpartum.
- the early application of Si Mo Tang is effective in preventing and treating infantile dyspepsia and abdominal distension in the elderly.
- Si Mo Tang has the effect of enhancing gastrointestinal motility, promoting secretion of digestive juice, regulating gastrointestinal function, eliminating gastrointestinal stagnation, and is suitable for the treatment of functional dyspepsia.
- the woody notes in the four-mill soup contain active ingredients such as costunolide and dehydro-hydroaromatic lactone, which can excite the large intestine, strengthen the contractile force, accelerate the peristalsis, and relieve the bloating caused by the bloating of the stomach. It promotes gastric emptying and intestinal propulsion, and has an antagonistic effect on intestinal tendon caused by acetylcholine and histamine.
- active ingredients such as costunolide and dehydro-hydroaromatic lactone
- clam shell can enhance the tension of the small intestine smooth muscle, strengthen the small intestine peristalsis, and increase the gastrointestinal contraction rhythm.
- synephrine has a regulating effect on gastrointestinal motility, mainly through the regulation of acetylcholine receptor, adrenergic receptor, 5-HT receptor on smooth muscle cell membrane, and direct effect on smooth muscle cells.
- One of the active ingredients of the gastrointestinal movement of the clam shell. Arecaidine and its main active ingredient, arecolidine, can excite M-choline receptors, causing increased secretion of glands, exuding digestive juices, and exciting intestinal smooth muscles, which can cure food, qi stagnation, and bloating. , constipation, etc.
- Black medicine plays a key role in the group, not only can enhance the distribution
- the pharmacological effects of other drugs in the prescription but also can stimulate the gastrointestinal smooth muscle to strengthen its contractile activity, can accelerate blood circulation, and promote intestinal peristalsis.
- the main active ingredient in the black medicinal herb contains the other kind of water-soluble isoquinoline alkaloids such as norisobolidine, new wood ginger. Laurolitsine, reticuline, etc. Among them, norisobolidine has become the content control index of the Chinese Pharmacopoeia 2010 Pharmacopoeia.
- the existing measurement methods are mainly for the analysis and determination of one of the above components in the medicinal materials, other compound Chinese herbal preparations and biological samples.
- arecoline the existing methods mainly involve the determination of arecoline content in betel nut and human saliva by high performance liquid chromatography.
- the existing methods mainly involve capillary electrophoresis electrochemical detection, flow injection chemiluminescence, LC-MS, reversed-phase ion-pair high performance liquid chromatography for determination of citrus, clam shell, green skin, citrus, breast milk.
- norbibeldine the existing methods mainly involve high performance liquid chromatography for the determination of norbibelidine in the plasma of rats and rats.
- the technical problem to be solved by the present invention is to provide a simple, economical, and effective method for simultaneously determining three alkaloids of arecoline, synephrine and nor formoprene in a Si Mo Tang preparation to meet The need for quality inspection and control of Si Mo Tang preparations.
- the detection method of the present invention comprises the following steps: the test product of the Si Mo Tang preparation is subjected to high performance liquid chromatography, and the chromatographic conditions of the high performance liquid chromatography are any one of the following: Method 1: The column is a strong cationic exchange chromatography column, and the mobile phase has a volume ratio of 40 to 80: 60 to 20, more preferably 45 to 80: 55 to 20, preferably 65: 35 methanol and volume. a 0.2%, H 3.8 aqueous phosphoric acid solution with a detection wavelength of 215 nm;
- Method 2 The column is an 18-inch silicon germanium bonded silica gel column.
- the mobile phase is methanol with a volume ratio of 50:50 and a 0.1% SDS aqueous solution.
- the flow rate is as shown in Table 1, and the detection wavelength is 230 nm.
- the four-mill soup is an existing Chinese medicine prescription, and includes four kinds of herbs, such as woody, oyster shell, black peony and betel nut, and the ratio of parts by weight of each medicinal material is generally 100: 50-150: 50-150: 50 ⁇ 150.
- the preparation of the four-mill soup is the preparation of the existing four-mill soup according to various dosage forms prepared by the traditional Chinese medicine of Si Mo Tang, such as an oral liquid (such as the four-milling oral liquid disclosed in Chinese Patent No. CN1106288), and a pill (such as a honey pill).
- the above-mentioned four-mill soup preparation can be obtained by the following method: the volatile component extracted by the steam distillation method of the original medicinal material, and the aqueous extract extracted by the water-lifting alcohol precipitation of the medicinal slag are prepared into various dosage forms according to the existing method.
- the test sample of the above-mentioned four-mill soup preparation can be pre-treated according to the conventional chromatographic test solution.
- the pore size of the microporous membrane can be selected according to conventional conditions, and is generally 0.22 to 0.8 ⁇ m, preferably 0.45 ⁇ m.
- Various types of microporous membranes are suitable for use in the present invention, such as polyethersulfone microporous membranes.
- the solution in which the Si Mo Tang preparation is dissolved may be sonicated, cooled, and then filtered through a microporous membrane (same as described above), and the filtrate is supplied.
- the solvent in the solution in which the Si Mo Tang preparation is dissolved may be methanol, ethanol, 40% by volume or more of methanol aqueous solution, 40% by volume of aqueous ethanol solution, chloroform, ethyl acetate, diethyl ether, petroleum Ether, acetone or cyclohexane, the first four are preferred.
- the amount of the solvent used is such that the concentration of the Si Mo Tang preparation is suitable for chromatographic detection. Specifically, according to the concentration of the above-mentioned Si Mo Tang oral liquid for testing the sample, the same concentration can be formulated according to the dosage of the other Si Mo Tang preparation.
- the conditions of the sonication are preferably 160 to 250 W, the frequency is 40 kHz, and the ultrasound is 20 to 60 min.
- the amount of the injection detected by the high performance liquid chromatography is selected according to the conventional conditions in the field of chromatographic detection, and is generally 2 to 5 ( ⁇ L, preferably 5 to 2 ( ⁇ L is preferred).
- the strong cationic exchange chromatography column can be various types of strong cationic exchange chromatography columns, such as a sulfonic acid cation exchange column.
- the type specification of the strong cationic exchange chromatography column can be various existing specifications, such as 4.6mmX 250mm, 4.6mm X 150mm, etc., and most preferably 4.6mm X 250mm.
- the particle size of the filler of the strong cationic exchange chromatography column is preferably 5 ⁇ m.
- An Agilent SCX column (4.6 x 250 mm, particle size 5 ⁇ ) is particularly preferred in the present invention.
- the octadecyl silicon germanium bonded silica column can be an existing 18 ⁇ silicon germanium bonded silica column of various types and specifications, such as 4.6 mm X 250 mm, 4.6 mm. X 150mm equal length gauges are available, most preferably 4.6mm X 250mm.
- the particle size of the 18 ⁇ ⁇ silicon germanium bonded silica gel column is preferably 5 ⁇ m.
- An Agilent ZORBAX SB-C 18 column (4.6 x 250 mm, particle size 5 ⁇ ) is particularly preferred in the present invention.
- the column temperature has little effect on the separation effect, and the conventional one can be used.
- the temperature range in which the column can be used is generally 15 to 50 ° C, preferably 30 to 40 ° C, and most preferably 35 ° C.
- the flow rate has little effect on the separation effect of the detection method of the present invention, and can be selected according to a conventional method in the art, generally 0.5 to 1.5 mL/min, preferably 0.8 to 1.2 mL/min, preferably. It is 1 mL / min.
- Mode 2 of the method of the present invention employs a gradient flow rate.
- the change may be a conventional gradient change mode in the HPLC field, preferably a linear gradient change mode.
- the reagents and starting materials used in the present invention are commercially available.
- the positive effects of the present invention are as follows:
- the detection method of the present invention can simultaneously determine three alkaloid components of arecoline, synephrine and normethorphanine in the Si Mo Tang preparation.
- the chromatographic peaks measured by the method have the best resolution, theoretical plate number, symmetry factor and peak purity, and have a good linear relationship with the peak area in a large concentration range, and have excellent precision and repeatability. Accuracy.
- the invention provides a simple, economical and effective analytical method for the quality control of the Si Mo Tang preparation.
- 1 is a chromatogram of the test solution of the method for eluting conditions 1, 2 and 4 in the method of the first method, in the chromatogram, in the chromatogram, 1 is synephrine, 2 is norbiphorol, 3 is arecoline.
- 2 is a chromatogram of the test solution of the method of the second method of elution conditions 1 and 3 for detecting the Si Mo Tang oral liquid in the first embodiment.
- 1 is synephrine
- 2 is norbibeldine
- 3 is Arecoline.
- Figure 3 is a chromatogram of the best elution conditions of Example 1, namely, Method 1 - Elution Condition 3 and Method 2 Elution Condition 2, Test Solution Solution and Si Mo Tang Oral Solution, wherein 1 is Xinfu Lin, 2 is norbipoldine, 3 is arecoline, A is the reference solution, and B is the test solution of the four mill soup oral solution.
- Figure 4 is the color of the test solution for the detection of the Si Mo Tang oral liquid by the method 1 at different column temperatures of Example 2.
- Spectrogram wherein A is 30 ° C, B is 35 ° C, C is 40 ° C ; 1 is synephrine, 2 is norbibeldine, and 3 is arecoline.
- Figure 5 is a chromatogram of the test solution for the detection of the Si Mo Tang oral solution by the method of Example 2 at different flow rates, wherein A is 0.8 mL/min, B is 1.0 mL/min, and C is 1.2 mL/min ; For synephrine, 2 is norbibeldine, and 3 is arecoline. detailed description
- Agilent 1100 liquid chromatograph (Agilent 1100, including quaternary pump, autosampler, column oven, detector, workstation), BP211D electronic analytical balance (Sartorius CO.).
- Si Mo Tang Oral Liquid is provided by Hunan Hansen Pharmaceutical Co., Ltd. or Hunan Zhongda Yuma Pharmaceutical Co., Ltd.
- Reference solution Take the arecoline hydrobromide, synephrine, and norpodazole reference substance, accurately weigh the weight, add methanol to dissolve, and prepare each 0.5 ml of arecoline hydrobromide, Sinfer A solution of 0.5 mg of meglumine and 0.4 mg of mesopoldine was used as a reference stock solution. Accurately draw 3 kinds of stock solutions, dilute with methanol to 1ml of arecoline hydrobromide 50 ⁇ ⁇ , Synephrine 50 ⁇ ⁇ , 40 ⁇ ⁇ of the reference solution of deisopoldine.
- the test solution of Si Mo Tang Oral Liquid Take 5 pieces of Si Mo Tang Oral Liquid, mix well, and filter with 0.45 ⁇ microporous membrane (0.45 ⁇ , polyethersulfone, SCAA-101 water phase needle filter) Continue the filtrate, that is.
- the column is Agilent SCX (4.6 x 250 mm, 5 ⁇ ), and the mobile phase is 45:55 methanol-0.2% (v/v) phosphoric acid aqueous solution (ammonia water ⁇ 3.8), column temperature is 15 °C, flow rate It is LSmL-min" 1 , the injection volume is 10 L, and the detection wavelength is 215 nm.
- the column is Agilent SCX (4.6 x 250 mm, 5 ⁇ ), and the mobile phase is 50:50 methanol -0.2% (v / V) phosphoric acid aqueous solution (ammonia water ⁇ 3.8), column temperature is 15 ° C, flow rate It is LSmL-min" 1 , the injection volume is 10 L, and the detection wavelength is 215 nm.
- the column is Agilent SCX (4.6 x 250 mm, 5 ⁇ ), and the mobile phase is methanol:0.2% (v/v) phosphoric acid in a volume ratio of 65:35 (ammonia pH 3.8), column temperature is 35 ° C, flow rate It is LOmL-min" 1 , the injection volume is 10 L, and the detection wavelength is 215 nm.
- the column is Agilent SCX (4.6 x 250 mm, 5 ⁇ ), and the mobile phase is methanol:0.2% (v/v) phosphoric acid in a volume ratio of 80:20 (ammonia pH 3.8), column temperature is 50 °C, flow rate It is O.SmL-mm 1 , the injection volume is 10 L, and the detection wavelength is 215 nm.
- the column is Agilent ZORBAX SB-C 18 (4.6 x 250 mm, 5 ⁇ ), the mobile phase is 50: 50 methanol-0.1wt% SDS aqueous solution, the column temperature is 50 °C, the flow rate is shown in Table 2, the injection 20 ⁇ , the detection wavelength is 230nm.
- the column is Agilent ZORBAX SB-C 18 (4.6 x 250 mm, 5 ⁇ ), the mobile phase is 50: 50 methanol-0.1wt% SDS aqueous solution, the column temperature is 35 ° C, the flow rate is shown in Table 3, the injection 20 ⁇ L, the detection wavelength was 230 nm.
- the column is Agilent ZORBAX SB-C 18 (4.6 x 250 mm, 5 ⁇ ), the mobile phase is 50: 50 methanol-0.1wt% SDS aqueous solution, the column temperature is 15 °C, the flow rate is shown in Table 4, the injection 20 ⁇ L, the detection wavelength was 230 nm.
- the chromatogram obtained by the method 1 elution conditions 1 to 4 and the method 2 elution conditions 1 to 3 is as shown in the figure. As shown in Tables 1 to 3, retention time, resolution, theoretical plate number, symmetry factor, and peak purity are shown in Table 5.
- the first method has a more excellent separation effect, and is more suitable for the application of synephrine and arecoline in the four-mill oral liquid. Separation and detection analysis with norbibeldine.
- the method has a good anti-interference ability for the change of the column temperature and the mobile phase flow rate.
- Example 3 Methodology Verification Dilute with methanol to a series of mixed reference standard solutions as shown in Table 6.
- the high-precision liquid chromatograph was separately injected into the high-performance liquid chromatograph, and the measurement was carried out according to the method-elution condition 3 in the first embodiment.
- Linear regression was performed with the chromatographic peak areas of synephrine, arecoline hydrobromide and norbipirin, respectively, to obtain a standard curve regression equation.
- the standard curves for synephrine, arecoline hydrobromide and norisopoldine are:
- the intra-day precision (RSD%) of synephrine at three concentrations was calculated to be 0.20, 0.16, and 0.26, respectively; the intra-day precision (RSD%) of norbibeldine at three concentrations were 0.22, 0.54, and 0.34, respectively.
- the intra-day precision (RSD%) of arecoline hydrobromide at three concentrations were 0.33, 1.03, and 1.14, respectively.
- the peak area was determined by the method-elution condition 3 in Example 1 for three consecutive days, and the daytime precision (RSD%) of the synephrine at three concentrations was calculated to be 1.00, 1.56 and 1.38, respectively.
- the intra-day precision (RSD%) of triisopoldine at three concentrations were 1.27, 1.58 and 1.56, respectively; the intra-day precision (RSD%) of arecoline hydrobromide at three concentrations were 0.81, 1.63 and 1.68, respectively. .
- the test solution of the Si Mo Tang Oral Liquid of Example 1 was injected at 0, 2, 4, 8, 12, 24 and 48 hours, respectively, and analyzed according to the method 1 and the elution condition 3 in Example 1, The peak area was determined and the stability of the peak areas of synephrine, arecoline and norisopoldine was calculated. The results were as follows: The RSD% of the area of synephrine, arecoline and norpodopidine were 1.57, 0.53, respectively. And 1.95, indicating that the three components in the Si Mo Tang oral solution are stable within 48 hours.
- the average recovery of synephrine was 99.05%, the RSD was 2.56%, the average recovery of arecoline hydrobromide was 96.24%, the RSD was 1.03%, the average recovery of norpodazole was 99.00%, and the RSD was 1.52%.
- the results are shown in Table 7.
- the content of synephrine, arecoline and nortebopolidine in the four batches of different manufacturers of Si Mo Tang oral liquid was determined. Take five sets of Si Mo Tang Oral Liquid for each batch of product, mix, shake, and pass 0.45 ⁇ membrane, and take the filtrate to obtain the test solution of Si Mo Tang Oral Liquid. The reference solution and the test solution were separately aspirated and injected, and analyzed according to the method 1 and the elution condition 3 in Example 1. Calculate the percentage according to the external standard method, as shown in Table 8.
- the average content of synephrine, norbiphordine and arecoline in 26 batches of Si Mo Tang samples were 0.024 ⁇ 0.005 mg mL" 1 , 0.041 ⁇ 0.009 mg mL" 1 and 0.029 ⁇ 0.007 mg mL -1 , respectively .
- 091243/448 has 0.040 0.049 0.037
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
一种四磨汤制剂的检测方法 技术领域
本发明涉及一种四磨汤制剂的检测方法。 背景技术
中成药四磨汤是一种快速排除胃肠积滞、 增强消化机能的验方。 该方主 要成分包括木香、枳壳、乌药和槟榔等药。其中, 木香、枳壳行气宽中和胃, 槟榔降逆气, 乌药散寒止痛。 诸药合用, 共奏行气导滞、 消胀止痛之功效。 临床主要用于婴幼儿乳食内滞, 中老年气滞食积, 以及腹部手术后、 产后促 进肠胃功能的恢复。四磨汤早期被用于防治婴幼儿消化不良及老年人腹部胀 气 均有明显疗效, 近年用于手术后胃肠功能恢复, 疗效显著, 安全可靠。 据药理学实验证明, 四磨汤具有增强胃肠蠕动, 促进消化液分泌, 调节胃肠 功能, 排除肠胃积滞作用, 适用于功能性消化不良的治疗。
四磨汤中的木香含有木香烃内酯 (costunolide) 、 去氢木香烃内酯等有 效成分, 能使大肠兴奋, 收缩力加强, 蠕动加快, 可缓解胃肠气胀所致的腹 胀, 对胃排空和肠推进均有促进作用, 对乙酰胆碱和组织胺所致的肠肌痉挛 有对抗作用。 枳壳及其所含的主要有效成分辛弗林 (synephrine ) 和 N-甲基 酪胺 (N-methyltyramine ) 等生物碱对胃肠道平滑肌有一定的兴奋作用, 可 使胃肠运动收缩节律性增加, 枳壳能增强小肠平滑肌紧张程度, 使小肠蠕动 加强, 胃肠收缩节律增快。 其中, 辛弗林对胃肠运动具有调节作用, 主要通 过平滑肌细胞膜上的乙酰胆碱受体、 肾上腺素受体、 5-HT受体调节, 以及对 平滑肌细胞的直接作用,进一歩肯定辛弗林为枳壳作用胃肠运动的有效成分 之一。 槟榔及其所含的主要有效成分槟榔碱 (arecolidine) 可兴奋 M-胆碱受 体, 引起腺体分泌增加, 使消化液分泌旺盛, 并具有兴奋肠平滑肌作用, 可 治食积、 气滞、 腹胀、 便秘等。 乌药在组方中起关键性作用, 不仅能增强配
方中其它药物的药理作用, 而且亦能兴奋胃肠平滑肌使其收缩活动加强, 可 以加速血液循环, 有促进肠蠕动的作用。 乌药中的主要活性成分除脂溶性成 分乌药醚内酯等外, 主要含有另一类水溶性更好的异喹啉类生物碱成分如去 甲异波尔定(norisobolidine),新木姜子碱(laurolitsine),牛心果碱(reticuline) 等。 其中去甲异波尔定 (norisobolidine) 已成为中国药典 2010版药典乌药药 材的含量控制指标。
槟榔碱 (式 1 ) 、 辛弗林 (式 2) 和去甲异波尔定 (式 3 ) 三种生物碱是 四磨汤口服液中发挥重要药理作用的主要成分。 因此, 建立一种简单、 经济 和有效的分析方法测定四磨汤口服液中上述三种生物碱成分,对控制药品质 量十分必要。
式 1 式 2 式 3
但现有的测定方法主要为针对在药材、其他复方中草药制剂及生物样品 中某一种上述成分的分析测定。 如有关槟榔碱, 现有方法主要涉及高效液相 色谱法测定槟榔子、 人类唾液中槟榔碱含量的测定。 有关辛弗林, 现有方法 主要涉及通过毛细管电泳电化学检测法、 流动注射化学发光法、 LC-MS法、 反相离子对高效液相色谱法测定枳实、 枳壳、 青皮、 柑橘、 母乳等中的辛弗 林含量的方法。 有关去甲异波尔定, 现有方法主要涉及高效液相色谱法测定 乌药、 大鼠血浆中去甲异波尔定的含量的方法。
针对四磨汤口服液, 目前仅有少量文献建立了测定其中槟榔碱或辛弗林 的含量的高效液相色谱法:文献 (HPLC法测定四磨汤口服液中辛弗林的含量. 中国医药导刊, 2009, 11(1): 165-166; 高效液相色谱法测定四磨汤口服液中 槟榔碱的含量, 湖南中医药大学学报, 2009, 29(4): 27-29)。 至今, 尚未见 可同时测定四磨汤制剂中槟榔碱、辛弗林和去甲异波尔定三种生物碱的方法
的报道。 发明内容
本发明所要解决的技术问题是提供一种简单、 经济、 且有效的, 可同时 测定四磨汤制剂中槟榔碱、 辛弗林和去甲异波尔定三种生物碱成分的方法, 以满足对四磨汤制剂质量考察和控制的需要。
本发明的检测方法包括如下歩骤:将四磨汤制剂的供试品进行高效液相 色谱法检测, 即可; 所述的高效液相色谱法的色谱条件为下述中的任一种: 方式一: 色谱柱为强阳离子型交换色谱柱, 流动相为体积比为 40〜80: 60〜20、更佳的为 45〜80: 55〜20、较佳的为 65: 35的甲醇和体积百分比 0.2%、 H 3.8的磷酸水溶液, 检测波长为 215 nm;
方式二: 色谱柱为十八垸基硅垸键合硅胶柱, 流动相为体积比 50: 50 的甲醇和质量百分比 0.1%SDS水溶液,流速如表 1所示,检测波长为 230nm。
表 1
本发明中, 所述的四磨汤为现有中药方, 其包括木香、 枳壳、 乌药和槟 榔四味药材, 各药材重量份数比一般为 100: 50-150: 50-150: 50〜150。 所 述的四磨汤制剂为现有的根据四磨汤中药方制备的各种剂型的四磨汤制剂, 例如口服液(如中国专利 CN1106288公开的四磨汤口服液)、丸剂(如蜜丸、 浓缩丸或滴丸)、 乳化剂、 胶囊 (如软胶囊)、 片剂 (如咀嚼片或泡腾片)、 干混悬剂、 口服凝胶剂、 颗粒剂或栓剂等。 上述四磨汤制剂可由下述方法制 得: 将原药材经水蒸气蒸馏法提取的挥发性成分, 与药渣经水提醇沉提取的 水提物, 按现有方法制成各剂型。
本发明中,所述的四磨汤制剂的供试品可按常规的色谱供试溶液的预处
理方法制备而得。 具体的, 对于四磨汤口服液, 可直接用微孔滤膜过滤, 滤 液可不经稀释, 或者稀释至原体积 100倍以下(稀释溶剂可为水或流动相), 即为供试品。所述的微孔滤膜的孔径可按常规条件选择,一般为 0.22〜0.8μηι, 优选 0.45μηι。 各种类的微孔滤膜均适用本发明, 如聚醚砜微孔滤膜。 对于 其他剂型(如其他液体制剂或固体制剂) 的四磨汤制剂, 可将溶有四磨汤制 剂的溶液经超声处理, 冷却, 之后用微孔滤膜(同前述) 过滤, 滤液即为供 试品。 其中, 所述的溶有四磨汤制剂的溶液中的溶剂可为甲醇、 乙醇、 体积 百分比 40%以上的甲醇水溶液、 体积百分比 40〜95%的乙醇水溶液、 氯仿、 乙酸乙酯、 乙醚、 石油醚、 丙酮或环己垸, 优选前四种。 所述的溶剂的用量 以使四磨汤制剂的浓度适宜色谱检测为准。 具体的, 可根据上述四磨汤口服 液供试品中的浓度, 按其他四磨汤制剂的药材用量折算配制成相同浓度。 所 述的超声处理的条件较佳的为 160〜250W, 频率 40kHz, 超声 20〜60min。
本发明中,所述的高效液相色谱法检测的进样量根据色谱检测领域常规 条件选择, 一般为 2〜5(^L, 以 5〜2(^L为佳。
本发明方法的方式一中,所述的强阳离子型交换色谱柱可为现有的各种 类型的强阳离子型交换色谱柱, 如磺酸基阳离子交换柱。 所述的强阳离子型 交换色谱柱的型号规格可为现有各种型号规格, 如 4.6mmX 250mm、 4.6mm X 150mm等径长规格均可适用, 最优选 4.6mm X 250mm。 所述的强阳离子 型交换色谱柱的填料粒径较佳的为 5μηι。 本发明特别优选 Agilent SCX柱 (4.6x250 mm , 填料粒径 5 μηι)。
本发明方法的方式二中,所述的十八垸基硅垸键合硅胶柱可为现有的各 种型号规格的十八垸基硅垸键合硅胶柱, 如 4.6mm X 250mm, 4.6mm X 150mm等径长规格均可适用, 最优选 4.6mm X 250mm。 所述的十八垸基硅 垸键合硅胶柱的填料粒径较佳的为 5μηι。 本发明特别优选 Agilent ZORBAX SB-C18柱 (4.6x250 mm, 填料粒径 5 μηι)。
本发明方法的方式一或二中, 柱温对分离效果影响不大, 可采用常规的
色谱柱可以允许使用的温度范围, 一般为 15〜50°C, 较佳的为 30〜40°C, 最 佳的为 35°C。
本发明方法的方式一中, 流速对本发明检测方法的分离效果影响不大, 可按本领域常规方法选择,一般为 0.5〜1.5 mL/min,较佳的为 0.8〜1.2 mL/min, 最佳的为 1 mL /min。
本发明方法的方式二采用梯度流速, 表 1中, 所述的改变可为 HPLC领 域常规的各种梯度变化方式, 较佳的为线性梯度改变方式。
在符合本领域常识的基础上, 上述各优选条件, 可任意组合, 即得本发 明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进歩效果在于: 本发明的检测方法可同时测定四磨汤制剂 中槟榔碱、 辛弗林和去甲异波尔定三种生物碱成分。 该方法所测得的色谱峰 的分离度、 理论塔板数、 对称因子、 峰纯度均较佳, 且在较大浓度范围内与 峰面积呈良好线性关系, 具有优异的精密度、 重复性和准确度。 本发明为四 磨汤制剂的质量控制提供了简单、 经济和有效可靠的分析方法。 附图说明
图 1为实施例 1中方法一洗脱条件 1、 2和 4检测四磨汤口服液的供试品溶 液的色谱图, 色谱图中 1为辛弗林, 2为去甲异波尔定, 3为槟榔碱。
图 2为实施例 1中方法二洗脱条件 1和 3检测四磨汤口服液的供试品溶液 的色谱图, 色谱图中 1为辛弗林, 2为去甲异波尔定, 3为槟榔碱。
图 3为实施例 1最佳洗脱条件, 即方法一洗脱条件 3和方法二洗脱条件 2 检测对照品溶液和四磨汤口服液的供试品溶液的色谱图, 其中 1为辛弗林, 2为去甲异波尔定, 3为槟榔碱, A为对照品溶液, B为四磨汤口服液的供试 品溶液。
图 4为实施例 2不同柱温下方法一检测四磨汤口服液的供试品溶液的色
谱图, 其中, A为 30°C, B为 35°C, C为 40°C ; 1为辛弗林, 2为去甲异波尔 定, 3为槟榔碱。
图 5 为实施例 2不同流速下方法一检测四磨汤口服液的供试品溶液的 色谱图, 其中, A为 0.8 mL/min, B为 1.0 mL/min, C为 1.2 mL/min; 1为 辛弗林, 2为去甲异波尔定, 3为槟榔碱。 具体实施方式
下面通过实施例的方式进一歩说明本发明,但并不因此将本发明限制在 所述的实施例范围之中。 下列实施例中未注明具体条件的实验方法, 按照常 规方法和条件, 或按照商品说明书选择。
下述实施例中, 所用设备和试剂:
Agilent 1100型液相色谱仪 (Agilent 1100, 包括四元泵、 自动进样器、 柱温箱、 检测器、 工作站) , BP211D电子分析天平 (Sartorius CO. )。
辛弗林 (Synephrine, 110727-200306) 、 氢溴酸槟榔碱 (Arecoline hydrobromide, 111684-200401 ) 对照品由中国生物制品检定所提供 (供含量 测定用) 。 去甲异波尔定(Norisoboldine) 由上海中药标准化研究中心提供, 纯度大于 98%。 磷酸、 甲醇为色谱纯, SDS等其余试剂均为分析纯, 水为超 纯水。
四磨汤口服液由湖南汉森制药股份有限公司或湖南中达骛马制药有限 责任公司提供。
实施例 1 系统适用性
1、 样品制备
对照品溶液: 分别取氢溴酸槟榔碱、 辛弗林、 去甲异波尔定对照品, 精 密称定重量, 加甲醇溶解, 分别制成每 lml含氢溴酸槟榔碱 0.5 mg、 辛弗林 0.5 mg、 去甲异波尔定 0.4 mg的溶液, 作为对照品贮备溶液。 分别精密吸取 3种贮备液适量, 用甲醇稀释成 lml含氢溴酸槟榔碱 50 μ§、 辛弗林 50 μ§、
去甲异波尔定 40 μ§的对照品溶液。
四磨汤口服液的供试品溶液:取四磨汤口服液 5支,混合均匀,用 0.45μηι 微孔滤膜 (0.45μηι, 聚醚砜, SCAA-101水相针式滤器) 过滤, 取续滤液, 即得。
2、 色谱方法
(1) 方法一
洗脱条件 1:
色谱柱为 Agilent SCX (4.6 x250 mm, 5 μηι), 流动相为体积比 45: 55 的甲醇 -0.2 % (ν/ V) 磷酸水溶液 (氨水调 ρΗ3.8), 柱温为 15°C, 流速为 LSmL-min"1, 进样量 10 L, 检测波长为 215nm。
洗脱条件 2:
色谱柱为 Agilent SCX (4.6 x250 mm, 5 μηι), 流动相为体积比 50: 50 的甲醇 -0.2 % (ν/ V) 磷酸水溶液 (氨水调 ρΗ3.8), 柱温为 15°C, 流速为 LSmL-min"1, 进样量 10 L, 检测波长为 215nm。
洗脱条件 3 (最佳洗脱条件):
色谱柱为 Agilent SCX (4.6 x250 mm, 5 μηι), 流动相为体积比 65: 35 的甲醇 -0.2 % (ν/ V) 磷酸水溶液 (氨水调 ρΗ3.8), 柱温为 35°C, 流速为 LOmL-min"1, 进样量 10 L, 检测波长为 215nm。
洗脱条件 4:
色谱柱为 Agilent SCX (4.6 x250 mm, 5 μηι), 流动相为体积比 80: 20 的甲醇 -0.2 % (ν/ V) 磷酸水溶液 (氨水调 ρΗ3.8), 柱温为 50°C, 流速为 O.SmL-mm1, 进样量 10 L, 检测波长为 215nm。
(2) 方法二
洗脱条件 1:
色谱柱为 Aglient ZORBAX SB-C18 (4.6 x250 mm, 5 μηι), 流动相为体 积比 50: 50甲醇 -0.1wt%SDS水溶液, 柱温为 50°C, 流速如表 2所示, 进样
20μ , 检测波长为 230nm。
洗脱条件 2 (最佳洗脱条件):
色谱柱为 Aglient ZORBAX SB-C18 (4.6 x250 mm, 5 μηι), 流动相为体 比 50: 50甲醇 -0.1wt%SDS水溶液, 柱温为 35°C, 流速如表 3所示, 进样 20μL, 检测波长为 230nm。
表 3
洗脱条件 3、
色谱柱为 Aglient ZORBAX SB-C18 (4.6 x250 mm, 5 μηι), 流动相为体 比 50: 50甲醇 -0.1wt%SDS水溶液, 柱温为 15°C, 流速如表 4所示, 进样 20μL, 检测波长为 230nm。
表 4
3、 实验结果
采用方法一洗脱条件 1〜4、 以及方法二洗脱条件 1〜3所得的色谱图如图
1〜3所示, 保留时间、 分离度、 理论塔板数、 对称因子和峰纯度如表 5所示。
表 5 方法一和方法二的分离效果
由图 1〜3, 表 5可见, 方法一和方法二均可满足分离要求。 但以方法一 和二的最佳洗脱条件相比较, 方法二测定的 3种生物碱色谱峰的对称因子为
0.61-0.69, 而方法一的对称因子提高到 0.86〜0.92; 与方法二相比, 方法一 测定的 3种生物碱色谱峰的理论塔板数和分离度, 除去甲异波尔定有所降低 以外, 辛弗林和槟榔碱均大大提高, 从而极大提高了检测灵敏度。 此外, 方 法一所得色谱峰的峰纯度均显著优于方法二。 因此, 由上述结果表明, 与采 用 ODS反相色谱柱 ZORBAX SB-C18的方法二相比,方法一具有更加优异的分 离效果, 更加适用于对四磨汤口服液中辛弗林、 槟榔碱和去甲异波尔定的分 离和检测分析。
实施例 2 耐用性试验
1、 柱温的影响
实验方法:取实施例 1的四磨汤口服液的供试品溶液,分别在柱温 30°C、 35°C和 40°C条件下进行分析, 其他条件同实施例 1中方法一洗脱条件 3。
实验结果: 色谱图如图 4所示。 由图 4可见, 柱温在 30〜40°C之间时, 对色谱峰的保留时间有一定的影响, 但对目的色谱峰的分离情况影响不大。 当柱温为 40 °C,分离时间最短。因此 30〜40°C的柱温均可适用方法一的测定。
2、 流速的影响
实验方法: 取实施例 1的四磨汤口服液的供试品溶液, 分别在不同流速 0.8 mL/min, 1.0 mL/min和 1.2 mL/min的条件下进行分析, 其他条件同实施 例 1中方法一洗脱条件 3。
实验结果: 色谱图如图 5所示。 由图 5可见, 3种不同的流速对色谱峰分 离度影响不大, 但对色谱峰的保留时间影响较大, 高流速下分析时间大大 缩短。 因此, 流速 O.S l^ miivmU1的流速均可适用方法一的测定。
由上述实验可见,方法一对柱温和流动相流速的变化有良好的抗干扰能 力。
实施例 3 方法学验证
用甲醇稀释成如表 6所示的系列混合对照品标准溶液
表 6混合对照品系列标准溶液
分别精密吸取 10 混合对照品标准溶液注入高效液相色谱仪, 按实施 例 1中方法一洗脱条件 3进行测定。 分别以辛弗林、 氢溴酸槟榔碱和去甲异波 尔定的色谱峰面积与相对应的浓度进行线性回归, 得标准曲线回归方程。 结 果辛弗林、 氢溴酸槟榔碱和去甲异波尔定的标准曲线分别为:
辛弗林: y= 18027X+12.397, r=0.9999;
氢溴酸槟榔碱: y = 20543X+ 10.22, r=0.9999;
去甲异波尔定: y = 46596X-1.189, r=l。
辛弗林、 氢溴酸槟榔碱和去甲异波尔定分别在 JS^SS gmL^ 1.30〜 208 g mL—1和 2.015〜201.6 mL—1的线性范围内线性关系良好。
二、 最低定量限与最低检测限
用甲醇配制不同浓度的含辛弗林、 去甲异波尔定、 氢溴酸槟榔碱的混合 对照品溶液, 摇匀, 进样 10 L, 按实施例 1中方法一洗脱条件 3分析。 信 噪比 S/N=10时, 辛弗林、 去甲异波尔定和氢溴酸槟榔碱的最低定量限分别 ¾ 2.55 μ mL"1, 2.015 g mL 和 1.30 ml/ 信噪比 S/N = 3时, 辛弗林、 去甲异波尔定和氢溴酸槟榔碱的最低检测限分别为 l^S gmL— 1.21μ§ mL"1 和 0.78 gmlA
三、 精密度考察
分别取下述三种浓度的混合对照品标准溶液: (1) SJ gmL 辛弗林、 20.1 mL—1去甲异波尔定和 13 g mL-1氢溴酸槟榔碱; (2) 51.(^g mL 辛弗林、40.32 g mL—1去甲异波尔定和 26.(^g mL—1氢溴酸槟榔碱;(3 )102.0μ§
mL 辛弗林、 SO A g mL 去甲异波尔定和 S .O g mL 氢溴酸槟榔碱。重复 进样 6次, 每次进样 10 L, 按实施例 1中方法一洗脱条件 3分析, 测定峰 面积。 计算辛弗林在三种浓度下的日内精密度 (RSD%) 分别为 0.20、 0.16 和 0.26; 去甲异波尔定在三种浓度下的日内精密度(RSD%)分别 0.22、 0.54 和 0.34; 氢溴酸槟榔碱在三种浓度下的日内精密度 (RSD%) 分别为 0.33、 1.03和 1.14。
分别连续三日按实施例 1中方法一洗脱条件 3进样分析, 测定峰面积, 计算辛弗林在三种浓度下的日间精密度(RSD%)分别为 1.00、 1.56和 1.38; 去甲异波尔定在三种浓度下的日内精密度(RSD%)分别 1.27、 1.58和 1.56; 氢溴酸槟榔碱在三种浓度下的日内精密度 (RSD%)分别为 0.81、 1.63和 1.68。
辛弗林、 氢溴酸槟榔碱和去甲异波尔定的日内和日间精密度 RSD均小 于 2%, 满足样品分析的要求。
四、 样品稳定性
取实施例 1的四磨汤口服液的供试品溶液, 分别在 0、 2、 4、 8、 12、 24 和 48小时进样 ΙΟμΙ^, 按实施例 1中方法一洗脱条件 3分析, 测定峰面积, 计算辛弗林、 槟榔碱和去甲异波尔定的峰面积的稳定性, 结果为: 辛弗林、 槟榔碱和去甲异波尔定峰面积的 RSD%分别为 1.57、 0.53和 1.95, 说明该四 磨汤口服液中三种成分在 48h内稳定。
五、 重复性实验
取 6份实施例 1的四磨汤口服液的供试品溶液, 进样 10 L, 按实施例 1中方法一洗脱条件 3分析, 测定峰面积, 结果为: 辛弗林、 槟榔碱和去甲 异波尔定的峰面积的 RSD%分别为 1.60、 1.04和 0.85, 表明该方法的重复性 良好。
六、 准确度与回收率实验
精密量取已准确测定辛弗林(0.02236mg/mL)、槟榔碱( 0.03516mg/mL) 和去甲异波尔定(0.03940mg/mL)含量的四磨汤口服液(批号 090436)2.5 mL,
置 5 mL量瓶中, 分别加入各自成分含量 50wt%、 100wt%、 120wt%的对照 品溶液, 加甲醇至刻度, 摇匀, 过滤。按实施例 1中方法一洗脱条件 3分析, 计算方法的准确度和回收率。 辛弗林平均回收率为 99.05%, RSD为 2.56%, 氢溴酸槟榔碱平均回收率为 96.24%, RSD为 1.03%, 去甲异波尔定平均回 收率为 99.00%, RSD为 1.52%, 结果见表 7。
表 7方法一洗脱条件 3测定辛弗林、 槟榔碱和去甲异波尔定的
准确度和加样回收率 (n =3 )
四磨汤口服液的检测
测定 26批次不同厂家的四磨汤口服液中辛弗林、 槟榔碱和去甲异波尔 定含量。 每批次产品取五支四磨汤口服液, 混合、 摇匀、 过 0.45 μηι的膜, 取续滤液, 即为四磨汤口服液的供试品溶液。 分别吸取对照品溶液和供试品 溶液各 ΙΟμΙ^, 进样, 按实施例 1中方法一洗脱条件 3进行分析测定。 按外 标一点法计算百分含量, 如表 8所示。 26批四磨汤样品中辛弗林、去甲异波 尔定、槟榔碱的平均含量分别为 0.024 ± 0.005 mg mL"1, 0.041 ± 0.009 mg mL"1 禾口 0.029士 0.007 mg mL-1。
表 8 26批次四磨汤口服液中辛弗林、 槟榔碱和去甲异波尔定的含量测定 (n=2 )
含量 (mg mL—1 )
批号 生广厂家
辛弗林 去甲异波尔定 槟榔碱
070109 0.021 0.021 0.026
070419 0.024 0.024 0.036
070706 0.031 0.042 0.024
071017 湖 0.022 0.028 0.022
080121 南 0.021 0.036 0.026
080421 汉 0.018 0.040 0.023
080712 0.022 0.041 0.025
081036 制 0.027 0.038 0.027
090225/731 药 0.027 0.044 0.030
090628/477 股 0.027 0.056 0.043
091026/470 份 0.034 0.054 0.035
091243/448 有 0.040 0.049 0.037
090424 限 0.024 0.044 0.021
090425 公 0.025 0.046 0.033
090426 司 0.024 0.046 0.028
090435 0.027 0.046 0.042
090436 0.022 0.039 0.035
20060311 0.020 0.040 0.023
20060601 0.015 0.042 0.036 湖南
20060905 0.019 0.046 0.037 中达
20061203 0.022 0.042 0.029 骜马
20070308 0.022 0.039 0.026 制药
20070624 0.028 0.043 0.019 有限
20070918 0.021 0.021 0.028 责任
20071201 0.019 0.042 0.022 公司
20080306 0.026 0.043 0.028
\ 0.024±0.005 0.041±0.009 0.029±0.007
Claims
1、 一种四磨汤制剂的检测方法, 其特征在于其包括如下歩骤: 将四磨汤制 剂的供试品进行高效液相色谱法检测, 即可; 所述的高效液相色谱法的色谱 条件为下述中的任一种:
方式一: 色谱柱为强阳离子型交换色谱柱, 流动相为体积比为 40〜80: 60〜20、更佳的为 45〜80: 55〜20、最佳的为 65: 35的甲醇和体积百分比 0.2%、 H 3.8的磷酸水溶液, 检测波长为 215 nm;
方式二: 色谱柱为十八垸基硅垸键合硅胶柱, 流动相为体积比 50: 50 的甲醇和质量百分比 0.1%SDS水溶液,流速如表 1所示,检测波长为 230nm;
表 1
所述的改变较佳的为线性梯度改变。
2、 如权利要求 1所述的方法, 其特征在于: 所述的四磨汤制剂主要由 下述重量份数的原药材制得: 100份木香、 50〜150份枳壳、 50〜150份乌药 和 50〜150份槟榔。
3、 如权利要求 2所述的方法, 其特征在于: 所述的四磨汤制剂为由下 述方法制得的四磨汤制剂: 将原药材经水蒸气蒸馏法提取的挥发性成分, 与 药渣经水提醇沉提取的水提物,按现有常规方法制成口服液、丸剂(如蜜丸、 浓缩丸或滴丸)、 乳化剂、 胶囊 (如软胶囊)、 片剂 (如咀嚼片或泡腾片)、 干混悬剂、 口服凝胶剂、 颗粒剂或栓剂。
4、 如权利要求 1所述的方法, 其特征在于: 所述的四磨汤制剂的供试 品按下述方法制得: 当所述的四磨汤制剂为四磨汤口服液时,直接将四磨汤口服液用微孔滤 膜过滤, 滤液不经稀释, 或经稀释至原体积 100倍以下, 即为供试品;
当所述的四磨汤制剂为除四磨汤口服液外的其他剂型时,将溶有四磨汤 制剂的溶液经超声处理, 冷却, 之后用微孔滤膜过滤, 滤液即为供试品。
5、 如权利要求 1所述的方法, 其特征在于: 所述的高效液相色谱法检 测的进样量为 2〜50μΙ^。
6、 如权利要求 1所述的方法, 其特征在于: 所述的强阳离子型交换色 谱柱为磺酸基阳离子交换柱, 较佳的为 Agilent SCX柱; 所述的十八垸基硅 垸键合硅胶柱为 Agilent ZORBAX SB-C18柱。
7、 如权利要求 1或 6所述的方法, 其特征在于: 所述的强阳离子型交 换色谱柱或十八垸基硅垸键合硅胶柱的径长规格为 4.6mm X 250mm 或 4.6mm X 150mm。
8、 如权利要求 7所述的方法, 其特征在于: 所述的强阳离子型交换色 谱柱或十八垸基硅垸键合硅胶柱的填料粒径为 5 μηι。
9、 如权利要求 1所述的方法, 其特征在于: 所述的方式一或方式二中, 柱温为 15〜50°C, 较佳的为 30〜40°C, 最佳的为 35°C。
10、 如权利要求 1所述的方法, 其特征在于: 所述的方式一中, 流速为 0.5〜1.5 mL / min, 较佳的为 0.8〜1.2 mL / min, 最佳的为 l mL / min。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110125049.6 | 2011-05-13 | ||
CN2011101250496A CN102346177B (zh) | 2011-05-13 | 2011-05-13 | 一种四磨汤制剂的检测方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012155376A1 true WO2012155376A1 (zh) | 2012-11-22 |
Family
ID=45545047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/075806 WO2012155376A1 (zh) | 2011-05-13 | 2011-06-16 | 一种四磨汤制剂的检测方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102346177B (zh) |
WO (1) | WO2012155376A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112505173A (zh) * | 2015-07-01 | 2021-03-16 | 广州中医药大学第一附属医院 | 一种陈皮中辛弗林含量的测定方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103940935A (zh) * | 2013-01-23 | 2014-07-23 | 中国农业科学院兰州畜牧与兽药研究所 | 一种动物血浆中氢溴酸槟榔碱含量的测定方法 |
CN104459003B (zh) * | 2014-12-16 | 2016-01-20 | 湖南汉森制药股份有限公司 | 缩泉制剂标准指纹图谱及特征图谱的构建方法及质量检测方法 |
CN105301158A (zh) * | 2015-10-22 | 2016-02-03 | 湖南汉森制药股份有限公司 | 一种四磨汤口服液的指纹图谱测定方法 |
CN107290468B (zh) * | 2017-06-06 | 2019-02-05 | 山东省药学科学院 | 一种液质联用定量检测小儿消食片中槟榔碱含量的方法 |
CN109425677B (zh) * | 2017-09-04 | 2021-08-10 | 天津中新药业研究院有限公司 | 一种解表化湿理气和中药物的质量控制方法 |
CN108445131B (zh) * | 2018-03-19 | 2020-06-23 | 湖南中医药大学 | 一种食用槟榔中主要成分的检测方法 |
CN111450185B (zh) * | 2020-05-14 | 2021-07-20 | 湖南汉森制药股份有限公司 | 四磨汤软胶囊及其制备方法 |
CN114689776B (zh) * | 2020-12-31 | 2023-05-26 | 四川新绿色药业科技发展有限公司 | 一种乌药汤高效液相特征图谱的构建方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004137218A (ja) * | 2002-10-18 | 2004-05-13 | Nagase & Co Ltd | 脂肪分解促進剤ならびにそれを用いた皮膚外用剤および飲食物 |
CN101366849A (zh) * | 2007-08-15 | 2009-02-18 | 未名天人中药有限公司 | 一种中药枳实的质量控制方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1778369A (zh) * | 2004-11-26 | 2006-05-31 | 湖南中达骛马制药有限责任公司 | 四磨汤 |
-
2011
- 2011-05-13 CN CN2011101250496A patent/CN102346177B/zh active Active
- 2011-06-16 WO PCT/CN2011/075806 patent/WO2012155376A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004137218A (ja) * | 2002-10-18 | 2004-05-13 | Nagase & Co Ltd | 脂肪分解促進剤ならびにそれを用いた皮膚外用剤および飲食物 |
CN101366849A (zh) * | 2007-08-15 | 2009-02-18 | 未名天人中药有限公司 | 一种中药枳实的质量控制方法 |
Non-Patent Citations (2)
Title |
---|
JIANG,AIBO ET AL.: "Study on quality control of Simotang chewable tablets.", CHIN HOSP PHARM J., vol. 26, no. 8, August 2006 (2006-08-01), pages 968 - 969 * |
YAO,YING ET AL.: "Determination of arecoline in Simotang oral solution with HPLC.", JOURNAL OF TCM UNIV. OF HUNAN., vol. 29, no. 4, August 2009 (2009-08-01), pages 27 - 29 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112505173A (zh) * | 2015-07-01 | 2021-03-16 | 广州中医药大学第一附属医院 | 一种陈皮中辛弗林含量的测定方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102346177A (zh) | 2012-02-08 |
CN102346177B (zh) | 2013-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012155376A1 (zh) | 一种四磨汤制剂的检测方法 | |
WO2012129847A1 (zh) | 四磨汤制剂的多指标成分同时测定及其指纹图谱构建方法 | |
CN103207255A (zh) | 一种脑心通胶囊的含量检测方法 | |
WO2019072247A1 (zh) | 一种中药组合物的超高效液相色谱检测方法 | |
CN103698432B (zh) | 测定荔枝核提取物中皂苷含量的方法 | |
CN102784275B (zh) | 通滞苏润江片及其制备和质量控制方法 | |
CN112526014B (zh) | 一种金茵利胆口服液指纹图谱及其建立方法 | |
CN101647993B (zh) | 一种用于治疗流行性感冒的药物及其制备和检测方法 | |
CN105911192A (zh) | 一种半枫荷活血化瘀活性部位的提取方法及指纹图谱检测方法 | |
CN105434555A (zh) | 一种热淋清制剂的制作方法 | |
CN103301177B (zh) | 长柱十大功劳总生物碱的制备及其质量控制方法 | |
CN102846704B (zh) | 一种益母草注射液、其制备方法和总生物碱的检测方法 | |
CN102552478A (zh) | 九味痔疮胶囊的质量检测方法 | |
CN104597197B (zh) | 一种消积通便药物制剂的检测方法 | |
WO2009155755A1 (zh) | 巴戟天寡糖的含量测定方法 | |
CN104483411B (zh) | 一种连翘及含连翘产品的检测方法 | |
CN100402059C (zh) | 舒筋定痛制剂的质量控制方法 | |
CN110988198A (zh) | 一种痹痛宁胶囊的含量测定方法 | |
CN102552356A (zh) | 一种无糖型灯盏细辛合剂的质量控制方法 | |
CN110530990A (zh) | 一种云实感冒合剂的检测方法 | |
CN101380441A (zh) | 一种调经养血,温暖子宫,驱寒止痛中药制剂的质量标准及其检验方法 | |
CN101766708A (zh) | 一种治疗风湿的中药制剂的质量控制方法 | |
CN110196299B (zh) | 复视明胶囊的指纹图谱及其在质量控制与成分分析中的应用 | |
CN107582639A (zh) | 一种醋延胡索配方颗粒及其制备方法 | |
CN110687219B (zh) | 一种苏黄止咳胶囊指纹图谱的检测方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11865686 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11865686 Country of ref document: EP Kind code of ref document: A1 |